Pfizer (PFE) Short-term Investments (2009 - 2026)

Pfizer (PFE) has reported Short-term Investments for 18 consecutive years, with $11.4 billion the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments fell 28.42% year-over-year to $11.4 billion; the TTM figure through Mar 2026 stood at $11.4 billion (down 28.42% YoY), while the FY2025 annual figure was $12.5 billion, down 35.92% from the prior year.
• Short-term Investments fell to $11.4 billion in Q1 2026 per PFE's latest filing, from $12.5 billion in the prior quarter.
• Across five years, Short-term Investments topped out at $42.2 billion in Q3 2023 and bottomed at $6.0 billion in Q2 2024.
• Historically, Short-term Investments has averaged $17.0 billion across 5 years, with a median of $13.6 billion in 2025.
• On a YoY basis, Short-term Investments climbed as much as 97.56% in 2024 and fell as far as 85.65% in 2024.
• Pfizer's Short-term Investments stood at $22.3 billion in 2022, then plunged by 55.92% to $9.8 billion in 2023, then surged by 97.56% to $19.4 billion in 2024, then tumbled by 35.92% to $12.5 billion in 2025, then dropped by 8.69% to $11.4 billion in 2026.
• Business Quant data shows PFE's Short-term Investments at $11.4 billion in Q1 2026, $12.5 billion in Q4 2025, and $13.6 billion in Q3 2025.